Table 2.
Demographic characteristics of patients who experienced adverse and hypersensitivity reactions
| HSR patients (n=436) |
Side effect patients (n=440) |
Total AR patients (n=876) |
p-value* | |
|---|---|---|---|---|
| Female | 238 (55) | 213 (48) | 451 (52) | 0.07 |
| Age (years), Med [IQR] | 52 [31, 67] | 59 [40, 74] | 56 [35, 70] | <0.001 |
| Race | 0.52 | |||
| White | 328 (75) | 337 (77) | 665 (76) | |
| Black | 22 (5) | 28 (6) | 50 (6) | |
| Asian | 22 (5) | 13 (3) | 35 (4) | |
| Hispanic | 4 (<1) | 4 (<1) | 8 (<1) | |
| American Indian | 2 (<1) | 0 (0) | 2 (<1) | |
| Other | 31 (7) | 30 (7) | 61 (7) | |
| Declined or unknown | 27 (6) | 28 (6) | 55 (6) | |
| Prior ADR | 171 (39) | 123 (28) | 294 (34) | <0.001 |
| Patient comorbidities | ||||
| Malignancy | 114 (26) | 113 (26) | 227 (26) | 0.88 |
| Atopic diseases | 95 (22) | 81 (18) | 176 (20) | 0.24 |
| Diabetes | 73 (17) | 97 (22) | 170 (19) | 0.05 |
| Renal failure | 71 (16) | 86 (20) | 157 (18) | 0.22 |
| Primary diagnosis † | ||||
| Circulatory system diseases | 63 (15) | 102 (23) | 165 (19) | 0.001 |
| Neoplasms | 61 (14) | 41 (9) | 102 (12) | 0.04 |
| Injury and poisoning | 42 (10) | 38 (9) | 80 (9) | 0.64 |
| Gastrointestinal diseases | 36 (8) | 36 (8) | 72 (8) | >0.99 |
| Respiratory diseases | 30 (7) | 35 (8) | 65 (7) | 0.61 |
| Highest level of care | ||||
| Inpatient | 250 (57) | 223 (51) | 473 (54) | 0.05 |
| Intensive care unit | 112 (26) | 152 (35) | 264 (30) | 0.005 |
| Cardiac care unit | 17 (4) | 26 (6) | 43 (5) | 0.21 |
| Emergency department | 36 (8) | 8 (2) | 44 (5) | <0.001 |
| Outpatient | 10 (2) | 9 (2) | 19 (2) | 0.82 |
| Neurologic intensive care unit | 3 (<1) | 13 (3) | 16 (2) | 0.02 |
| Unknown | 8 (2) | 9 (2) | 17 (2) | >0.99 |
| Length of stay (days), Med [IQR] ‡ | 6 [3, 14] | 11 [5, 23] | 9 [4, 19] | <0.001 |